Actively Recruiting
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
Led by Yongchang Zhang · Updated on 2024-09-19
186
Participants Needed
2
Research Sites
106 weeks
Total Duration
On this page
Sponsors
Y
Yongchang Zhang
Lead Sponsor
H
Hunan Province Tumor Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
CONDITIONS
Official Title
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed as advanced non-small cell lung cancer
- Confirmed mutation of KRAS, ALK, ERBB2, MET, RET, or BRAF
- Age between 18 and 75 years
You will not qualify if you...
- Diagnosed with small cell lung cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
2
Hunan Cancer hospital
Changsha, Hunan, China
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here